07252017Headline:

Lucrative Asia-Pacific Markets to Offer Significant Growth Opportunities for Players Operating in the Humanized Mouse Model Market

Growth in the humanized mouse model market is likely to be centered in the Asia-Pacific region. Growth in the Asia-Pacific can be attributed to the growing pharmaceutical industry in India, research in regenerative medicine in Japan, increasing investments from government and private sector in China’s life sciences sector, rising focus on personalized medicine in China, ongoing biomedical research activities in Australia, increase in animal research in Malaysia, and rising pharmaceutical and biotechnology R&D activities in South Korea.

The significance of China’s R&D capabilities has become increasingly important as an emerging force in the globalization of pharmaceutical R&D, thus fueling the use of humanized mouse models. China comprises about 20% of the global R&D spending and is second to the U.S. as the world’s largest investors in R&D. Cost savings and the lack of regulations have been one of the most important drivers to outsource preclinical activities in China. Sponsors could save about 30%–35% on the preclinical trial of a drug under investigation. Furthermore, the Chinese government has made it mandatory for all pharmaceutical and cosmetic products to be animal-tested before they are sold in the market. The need to test cosmetic and pharmaceutical compounds through humanized mouse is likely to bolster the demand for humanized mouse models in China.

Japan has been a leading market in the life sciences industry; various government and research institutes in Japan are also contributing to the growth in biomedical research. The Japan Society for the Promotion of Science and the Tokyo Biochemical Research Institute are among the prominent institutes that provide grants for biomedical research. Japan currently has a number of different organizations that conduct biomedical research, including the National Hospital Organization (NHO), National Institute of Radiological Science (NIRS), and National Institute of Biomedical Innovation (NIBIO). Moreover, Japan has also partnered with countries like Russia, India, the U.K., and others to jointly undertake biomedical research which is boosting the demand for research activities and the usage of mouse models. In addition to this, the rising investments in the field of regenerative medicine in Japan also favor the growth of the humanized mouse model market.

Development of bioclusters, growing presence of global players, and the rising R&D activities by pharmaceutical companies in the Indian market has encouraged research activities. In addition to this, Australia has been actively conducting biomedical research projects over the years. These projects make extensive use of animal models for the discovery, development, and commercialization of antibody-based medicines, thereby being a growth factor for the humanized mouse model market. Similarly, the heavy investments in translational and biomedical research that involves preclinical tasks encompassing animal testing has resulted in the growth of the market for humanized mouse models in Singapore.

 

What Next?

Recent Articles